Keloid scars are one of the most challenging problems for physicians and surgeons. These scars have been treated in many ways, with varying success. Verapamil is a widely used calcium channel antagonist, and it has been shown that calcium channel blockers inhibit the synthesis/secretion of extracellular matrix molecules, including collagen, glycosaminoglycans, and fibronectin, and increase collagenase. In this study, we performed total keloid excision in combination with reconstruction with W-plasty or skin grafting and injection of verapamil hydrochloride into the lesions of 21 patients with keloids. Patients were followed for minimum of 2 years, and the treatment outcome was evaluated based on the cosmetic appearances, symptomatic improvements, and the results of microscopic examinations. Also, patient satisfaction was scored with a visual analog scale. Two years after the operations, two patients had keloid in lesser diameter than the original lesions, two patients had lesions that were hypertrophic scars in appearance, and four patients had pruritus. One patient had keloid on the donor site. The rate of patient satisfaction was 6.4 on a scale of 1 to 10. We reviewed the treatment of keloid in this study and obtained one of the lower rates of complication in the literature. We believe that surgical excision with W-plasty or skin grafting and intralesional verapamil injection may be a good alternative in the treatment of keloid. 
Collagen synthesis and collagen degradation take place in a strictly controlled state of equilibrium. Loss of this equilibrium results in an abnormal tissue repair. Excessive collagen synthesis and/or failure of collagen degradation may lead to one of the most challenging squeals in the clinical practice. Keloid and hypertrophic scars result from an excessive collagen deposition, although the exact cause is still unknown. The etiology of keloid remains unclear, but genetic predisposition, pigmented skin, and imbalances in hormonal levels 1 are implicated. As cited in the review of Shaffer et al, 2 the first study about the keloid was presented in 1806 and since then more than a thousand articles have appeared in the literature about the pathogenesis and treatment of keloid. Nearly 200 years after the first study, treatment of this clinical condition is still a challenge for dermatologists, plastic surgeons, and physicians who give treat to scars. Keloids can be seen on all parts of the body. Generally, sternum and supradeltoid regions are the most affected parts, but also keloids of ears, 3 penis, 4 female genitalia, 5 corneum, 6 intraoral region, 7 and plantar region 8 have been reported. Different treatment modalities also have been reported in the literature, but most of them had a high recurrence rate. Surgery is an old technique and has a high recurrence rate in the treatment of keloid. 9 Lee et al 10 first reported the effect of verapamil on burn scars in the literature. Verapamil is a widely used calcium channel antagonist, and calcium channel blockers have been shown to inhibit synthesis/secretion of extracellular matrix molecules, including collagen, glycosaminoglycans, and fibronectin. In addition, they have been reported to increase collagenase and transforming growth factor-␤ activity. 11 Verapamil is a safe drug, and topical usage of this drug to treat Peyronie's disease and Dupuytren's contractures also has obtained successful results.
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PATIENTS AND METHODS
This study included 22 patients with keloids who were treated with surgical excision and intralesional verapamil injection and 1 patient who had hypertrophic scar after blepharoplasty operation and who was treated with intralesional verapamil injection in Izmir Atatürk Training Hospital and Adnan Menderes University Hospital. Patient data are summarized in Table 1 . Keloids that were fusiform in shape and no more than 10 mm in width were excised and reconstructed with W-plasty, and fullor split-thickness skin grafts were preferred in wider lesions. All specimens were examined pathologically. Intralesional verapamil hydrochloride injections were performed intraoperatively and on days 7, 14, 28, and during the second month after the operations. Intralesional verapamil injections to the donor sites were also performed in patients who underwent skin grafting. All patients received 2.5 mg/ml of verapamil hydrochlo- Journal of Burn Care & Rehabilitation ride, the doses of which varied from 0.5 to 5 ml depending on the size of keloids. Other treatment modalities, such as pressure garments and silicone sheets were not used. All patients were examined 1, 2, and 6 months and 2 years after the operations and recurrences, features of lesions, and symptoms were recorded (Figures 1-6 ).
Lesions were classified according to their appearances as very poor (rekeloid formation), poor (hypertrophic appearances), moderate (visible scar), good (acceptable scar), and excellent (invisible scar). Also, a visual analog scale was used to determine patient satisfaction, and biopsies were performed in five patients to evaluate the results 2 years after the operations.
RESULTS
All patients tolerated the surgical operations and injections well. There was no early or late complication as a result of the procedures. The pathological examination of excised specimens stained with Hematoxylin and eosin showed keloid in all lesions. Six patients noted tolerable pain caused by injections. Verapamil injection did not cause any side effects on the cardiovascular system or other systems. One month after the operations, all patients had scar formation, four patients (18%) had scars hypertrophic in appearance, and only one patient who underwent full-thickness skin graft had minimal keloid at the margins of the graft. Two patients had scars hypertrophic in appear- ance at the donor side. Ten patients had pruritus. Six months after the operations, six patients had scars that were hypertrophic in appearance on the keloid region, one patient had keloid formation at the margins of the graft, and one patient had keloid on the donor site. Just six patients had pruritus. Finally, 2 years after the operations, two patients had keloid in lesser diameter than the original lesions, two patients had lesions that looked like hypertrophic scars, and four patients had pruritus. One patient had keloid on the donor site. Patient satisfaction with the outcome was evaluated with a visual analog scale and scored as 0 for dissatisfaction and 10 for full satisfaction. The results are presented in Table 1 . Patient satisfaction varied from 2 to 9, with an average of 6.4. Biopsy was performed in patients who had keloid on the operation site and donor site. Microscopic examination demonstrated lesser collagen density and cellularity in these cases. None of the patients underwent a second operation.
DISCUSSION
Despite recent advances in the understanding of wound healing and scar formation, the treatment of keloid is still controversial. Although the combination of surgery with intralesional steroid injections is considered as the best approach, 14 -17 many treatment alternatives were described in the literature with Journal of Burn Care & Rehabilitation varying recurrence rates. The treatment protocols were summarized by Parker and include the following: excision (primary closure, local flap closure, homograft closure, keloid skin closure), cryosurgery, laser (argon, carbon dioxide, Nd:YAG laser), radiation therapy (primary, surgical adjuvant), steroids (intralesional, ointment, surgical adjuvant), pressure therapy, retinoic acid, penicillamine, colchicine, thiopeta, hyaluronidase, vitamin E, silicone sheet or gel, and interferon (interferon-alfa-2b, interferon-␥). 9 Comparisons of the treatment protocols are shown in Table 2 . The pathogenesis of keloid includes excessive amounts of collagen and other extracellular matrix components. 27 Abergel et al 28 showed an abnormal composition and metabolism of collagen in keloid tissue in their study. Fibroblasts from the keloid tissue have a greater amount of collagen type I, and when stimulated, they show an exaggerated proliferation. 29 Calcium channel blockers were first used in collagen matrix on the connective tissue remodeling by Lee and Ping in 1990. 30 They reported that verapamil reduced the incorporation of tritiated proline into the extracellular matrices of the fibroblast-populated collagen matrix by almost 50 to 60%. Doong et al 31 presented their observation about the calcium antagonists and claimed that calcium antagonists depolymerize actin filaments and alter the shape of fibroblast cells from bipolar to spherical and that this process results in an increase in procollagenase production. Topical applications of verapamil were also used in Peyronie's disease and Dupuytren's contracture because they affect the collagen metabolism. These effects can be summarized as the following: Calcium antagonist increases collagenase activity of the extracellular matrix and decreases the synthesis and secretion of collagen and fibronectin, altering the fibroblastic metabolism. Because the concentration of verapamil required to induce the degradative response in fibroblasts in the laboratory exceeds the safe serum levels by 100-fold or more, only intralesional therapy is possible at present. 13 The first successful results of the intralesional injection of verapamil were presented in 1994 in burn scars. 10 Lawrence 32 presented his experience with the intralesional verapamil injection and pressure therapy in the treatment of earlobe keloids and reported a cure rate of 55%. 32 Finally, D'Andrea et al 26 in their study in 2002 concluded that the treatment of keloids with perilesional surgical excision and topical silicone followed by an adjuvant treatment with intralesional verapamil hydrochloride injection at certain intervals offered a higher rate of resolution than other therapeutic strategies. In their study keloids were completely cured in 54% of the cases. The cure rate in the present study was greater than that in the study by D'Andreas, which revealed one of the most successful results in the literature. However, we did not use the treatment modalities, such as topical corticosteroid or pressure application, but we performed W-plasty or grafting in wider lesions. The major advantages of these techniques were that there was no skin tension because the defects were closed free of tension after the excision of keloids, but there also were disadvantages: the possibility of keloid formation in the donor site in the skin grafting group and the possibility of W-shaped excessive scarring in the other group. Fortunately, we had just one patient with a W-shaped scar. We believe that the application of verapamil to the donor site was a very valuable addition to the treatment of keloids.
In particular, a female patient treated with split-thickness skin grafting had an excellent scar in the donor side without keloid or hypertrophic scarring ( Figure  4 ), and the postblepharoplasty patient was satisfied with the outcome in the early term. However, the symptoms such as pruritus are very important in the clinic of the keloid, but most of the patients presented to our clinic with esthetic disfiguring of their scars. The patient satisfaction is as important as the cure of the lesion. To our knowledge, there has been no other study in the literature that reported the rates of patient satisfaction. We speculated that an acceptable appearance of the lesions after the treatment and resolution of pruritus are the most important criteria for the patient satisfaction. Shaffer et al 2 suggested that for any modality involving removal/debulking of a keloidal scar, a follow-up period of at least 12 months (and preferably 18 months) is needed to determine recurrences. We followed the patients for minimum of 24 months. We hypothesized that a large proportion of the patients with keloid were not optimistic about the treatment outcome before their admission. The high rate of satisfaction can be explained by the fact that we obtained acceptable results in the treatment of scars without keloid, although people believed that the treatment outcome was not going to be favorable.
CONCLUSIONS
No single technique has proven to be the definitive solution, and combination therapies generally give better results than any single-treatment modality. We speculate that surgical excision with W-plasty or skin grafting and intralesional verapamil injection may be a good alternative for the treatment of keloids.
